Its role Owner
AbbVie Inc. is a global research-based biopharmaceutical company headquartered in North Chicago, Illinois, formed in 2013 through the separation from Abbott Laboratories. The company discovers, develops, and manufactures therapies across immunology, oncology, neuroscience, eye care, virology, and aesthetics. Its portfolio includes adalimumab (Humira), risankizumab (Skyrizi), upadacitinib (Rinvoq), ibrutinib (Imbruvica, with Janssen), venetoclax (Venclexta, with Roche), and, following the 2020 acquisition of Allergan, products in medical aesthetics and ophthalmology. AbbVie is listed on the New York Stock Exchange under the ticker ABBV.
For the broader chemicals value chain, AbbVie’s operations span small‑molecule and biologics R&D, process development, and large‑scale manufacturing. Capabilities include API synthesis, cell culture and microbial fermentation for monoclonal antibodies and other biologics, as well as fill‑finish and packaging. The company runs a global manufacturing and supply network across the Americas, Europe, and Asia and operates under Good Manufacturing Practice (GMP) standards. AbbVie also engages in partnerships and licensing to advance pipeline candidates and technologies relevant to complex formulations, antibody engineering, and other advanced modalities.
chemXplore tracks 1 project involving AbbVie, of which one is active.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
Phase 4 STAR trial: guselkumab improved BASDAI at Week 24, reduced ASDAS‑CRP and MRI sacroiliac inflammation in biologic‑naïve axial PsA; safety profile consistent.
The trial's sole U.S. primary endpoint—overall survival—did not reach statistical significance; additional results will be submitted for peer review.
First bispecific‑based, chemotherapy‑free second‑line option in Europe after Phase 3 showed major PFS benefit and high complete response rates.
Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.
Fixed‑duration subcutaneous epcoritamab produced rapid, durable responses and high MRD negativity in elderly newly diagnosed DLBCL patients ineligible for full‑dose anthracycline therapy.
Post‑hoc subgroup analysis of the Phase 3 EPCORE FL‑1 shows epcoritamab+rituximab+lenalidomide delivers consistent PFS, ORR and CRR gains with a manageable safety profile across risk and fitness subgroups.
Epcoritamab shows improved progression-free survival in Phase 3 trial for R/R DLBCL. Safety profile consistent. Further analysis and regulatory discussions planned.
active all projects
